Meeting
2020 ASCO Virtual Scientific Program
Breast Cancer Index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial.
Authors
Gerrit-Jan Liefers
Leiden University Medical Center, Leiden, Netherlands
Gerrit-Jan Liefers , Iris Noordhoek , Kai Treuner , Hein Putter , Yi Zhang , Elma Meershoek – Klein Kranenbarg , Jenna Wong , Cornelis J. H. Van De Velde , Catherine A. Schnabel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NTR3077, BOOG 2006-05, Eudra-CT 2006-003958-16
Citation
J Clin Oncol 38: 2020 (suppl; abstr 512)
DOI
10.1200/JCO.2020.38.15_suppl.512
Abstract #
512
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.
First Author: G. Lunardi
Poster
2018 ASCO Annual Meeting
Adherence to hormonal therapy among commercially insured breast cancer patients.
First Author: Hui Zhao
Poster
2016 ASCO Annual Meeting
Tamoxifen versus aromatase inhibitors for the adjuvant treatment of breast cancer in older women: A feasibility study to examine differences in cognitive outcomes.
First Author: Emily Anne Underwood
Poster
2015 ASCO Annual Meeting
A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25).
First Author: Maysa M. Abu-Khalaf